IL99754A - תכשיר רוקחות המכיל אוטואנגד או חלקיק או אנלוג ממנו לטפול בדלקת המפרקים אוטואימונית ובמולטיפול סקלירוסיס - Google Patents
תכשיר רוקחות המכיל אוטואנגד או חלקיק או אנלוג ממנו לטפול בדלקת המפרקים אוטואימונית ובמולטיפול סקלירוסיסInfo
- Publication number
- IL99754A IL99754A IL9975491A IL9975491A IL99754A IL 99754 A IL99754 A IL 99754A IL 9975491 A IL9975491 A IL 9975491A IL 9975491 A IL9975491 A IL 9975491A IL 99754 A IL99754 A IL 99754A
- Authority
- IL
- Israel
- Prior art keywords
- mbp
- rats
- fed
- suppression
- disease
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 25
- 201000006417 multiple sclerosis Diseases 0.000 title claims description 17
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 206010071155 Autoimmune arthritis Diseases 0.000 title claims description 6
- 239000012634 fragment Substances 0.000 title abstract description 47
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 206010003246 arthritis Diseases 0.000 claims description 36
- 108010041390 Collagen Type II Proteins 0.000 claims description 24
- 102000000503 Collagen Type II Human genes 0.000 claims description 24
- 102000008186 Collagen Human genes 0.000 claims description 18
- 108010035532 Collagen Proteins 0.000 claims description 18
- 229920001436 collagen Polymers 0.000 claims description 18
- 102000006386 Myelin Proteins Human genes 0.000 claims description 14
- 108010083674 Myelin Proteins Proteins 0.000 claims description 14
- 210000005012 myelin Anatomy 0.000 claims description 11
- 241000283690 Bos taurus Species 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 102000001187 Collagen Type III Human genes 0.000 claims description 6
- 108010069502 Collagen Type III Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 241001465754 Metazoa Species 0.000 abstract description 82
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 42
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 34
- 238000000034 method Methods 0.000 abstract description 28
- 230000001404 mediated effect Effects 0.000 abstract description 10
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 184
- 102000047918 Myelin Basic Human genes 0.000 description 172
- 101710107068 Myelin basic protein Proteins 0.000 description 172
- 241000700159 Rattus Species 0.000 description 118
- 230000001629 suppression Effects 0.000 description 86
- 201000002491 encephalomyelitis Diseases 0.000 description 73
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 67
- 201000010099 disease Diseases 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 64
- 208000009386 Experimental Arthritis Diseases 0.000 description 57
- 230000035611 feeding Effects 0.000 description 55
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 43
- 210000004989 spleen cell Anatomy 0.000 description 39
- 102000036639 antigens Human genes 0.000 description 38
- 108091007433 antigens Proteins 0.000 description 38
- 239000000427 antigen Substances 0.000 description 35
- 230000003053 immunization Effects 0.000 description 35
- 238000002649 immunization Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 31
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 30
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
- 239000002953 phosphate buffered saline Substances 0.000 description 26
- 229940098773 bovine serum albumin Drugs 0.000 description 25
- 238000011694 lewis rat Methods 0.000 description 25
- 210000001165 lymph node Anatomy 0.000 description 25
- 230000006698 induction Effects 0.000 description 24
- 230000004044 response Effects 0.000 description 24
- 239000002671 adjuvant Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 238000012546 transfer Methods 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 17
- 241000700199 Cavia porcellus Species 0.000 description 16
- 108010058846 Ovalbumin Proteins 0.000 description 15
- 229940092253 ovalbumin Drugs 0.000 description 15
- 101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 14
- 230000001712 encephalitogenic effect Effects 0.000 description 14
- 230000009696 proliferative response Effects 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000011161 development Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- 210000004988 splenocyte Anatomy 0.000 description 11
- 201000008827 tuberculosis Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000003393 splenic effect Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 5
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 230000006472 autoimmune response Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010023232 Joint swelling Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101001018362 Bos taurus Myelin basic protein Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000004982 autoimmune uveitis Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 102000054064 human MBP Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- -1 semisolid Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101000685083 Centruroides infamatus Beta-toxin Cii1 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100137555 Mus musculus Prg2 gene Proteins 0.000 description 1
- 208000011644 Neurologic Gait disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000009171 T-cell vaccination Methods 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 210000002975 pon Anatomy 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001005 suppressogenic effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000011637 wistar furth rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Liquid Crystal (AREA)
- Liquid Crystal Display Device Control (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59693690A | 1990-10-15 | 1990-10-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL99754A0 IL99754A0 (en) | 1992-08-18 |
| IL99754A true IL99754A (he) | 1996-08-04 |
Family
ID=24389347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9975491A IL99754A (he) | 1990-10-15 | 1991-10-15 | תכשיר רוקחות המכיל אוטואנגד או חלקיק או אנלוג ממנו לטפול בדלקת המפרקים אוטואימונית ובמולטיפול סקלירוסיס |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6019971A (he) |
| EP (1) | EP0553291B1 (he) |
| JP (1) | JP2635444B2 (he) |
| KR (1) | KR0140841B1 (he) |
| AT (1) | ATE319474T1 (he) |
| AU (2) | AU9023791A (he) |
| CA (1) | CA2092905C (he) |
| DE (1) | DE69133516T2 (he) |
| ES (1) | ES2258261T3 (he) |
| HU (1) | HUT69942A (he) |
| IL (1) | IL99754A (he) |
| NO (1) | NO314878B1 (he) |
| WO (1) | WO1992006708A1 (he) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
| US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
| US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
| US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
| EP0553291B1 (en) * | 1990-10-15 | 2006-03-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by oral administration of autoantigens |
| DK0590060T3 (da) | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
| US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
| DE4125400C2 (de) * | 1991-07-31 | 2000-08-17 | Edwin Klaus | Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen |
| HU220357B (hu) * | 1992-02-28 | 2001-12-28 | Autoimmune Inc. | Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával |
| EP0662838A4 (en) * | 1992-09-25 | 1996-07-24 | Autoimmune Inc | PROCESS FOR THE TREATMENT OF RHUMATOID POLYARTHRITIS WITH TYPE II COLLAGEN. |
| DE69305313T3 (de) * | 1992-12-22 | 2001-06-21 | The University Of Cincinnati, Cincinnati | Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen |
| DK0609471T3 (da) * | 1993-02-02 | 2000-05-29 | Edwin Dr Klaus | Anvendelse af kollagen til behandling af sygelige ledprocesser |
| CA2164326A1 (en) * | 1993-06-02 | 1994-12-08 | Wayne Robert Thomas | Cryptic peptides for use in inducing immunologic tolerance |
| GB9319429D0 (en) | 1993-09-21 | 1993-11-03 | London Health Ass | Methods and products for controlling immune responses in mammals |
| US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| US5856446A (en) * | 1995-07-07 | 1999-01-05 | Autoimmune Inc. | Method of treating rheumatoid arthritis with low dose type II collagen |
| KR19990071782A (ko) * | 1996-01-05 | 1999-09-27 | 왈리스 조 앤 | 유형ⅱ 콜라겐의 제조방법 |
| AU3225097A (en) * | 1996-06-03 | 1998-01-05 | Auragen, Inc. | Immunotherapy for autoimmune disease |
| EP0939826A2 (en) * | 1996-08-15 | 1999-09-08 | Agrivax Incorporated | Delivery of tolerogenic antigens via edible plants or plant-derived products |
| US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7691829B2 (en) * | 1998-03-24 | 2010-04-06 | Petito George D | Composition and method for healing tissues |
| US20050208114A1 (en) * | 1998-03-24 | 2005-09-22 | Petito George D | Composition and method for healing tissues |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| US7462486B2 (en) * | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| WO2001085154A2 (en) * | 2000-05-12 | 2001-11-15 | Oregon Health Sciences University | Method of treating immune pathologies with low dose estrogen |
| ATE367823T1 (de) | 2000-05-24 | 2007-08-15 | Us Health | E-selectin zur behandlung oder vorbeugung von schlaganfall |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| CA2575604A1 (en) * | 2004-07-30 | 2006-02-02 | Oregon Health And Science University | Methods for detecting and treating autoimmune disorders |
| US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
| AR051528A1 (es) | 2004-12-15 | 2007-01-17 | Neuralab Ltd | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| CN104922199A (zh) * | 2015-07-14 | 2015-09-23 | 无限极（中国）有限公司 | 一种保护骨关节组合物及其应用 |
| EP3621985A4 (en) | 2017-05-11 | 2021-03-17 | Avicenna Nutraceutical, LLC | METHOD FOR GENERATING COLLAGEN |
| CA3154063A1 (en) | 2019-09-16 | 2021-03-25 | Figene, Llc | Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4350682A (en) * | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
| KR880701108A (ko) * | 1986-06-30 | 1988-07-25 | 원본미기재 | 면역조절 조성물 및 이들의 용도 |
| CA1302880C (en) * | 1986-07-25 | 1992-06-09 | Peter Koepff | Agents for the treatment of arthroses |
| ATE258065T1 (de) * | 1987-06-24 | 2004-02-15 | Brigham & Womens Hospital | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen |
| US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
| US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
| US5399347A (en) * | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
| CA1340012C (en) * | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
| ES2144398T3 (es) * | 1989-12-20 | 2000-06-16 | Autoimmune Inc | Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos. |
| US5075112A (en) * | 1990-02-12 | 1991-12-24 | Cartilage Technologies Inc. | Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage |
| JPH05508621A (ja) * | 1990-03-02 | 1993-12-02 | オートイミューン インク | 自己抗原の経口投与による自己免疫疾患のダウンコントロール |
| EP0553291B1 (en) * | 1990-10-15 | 2006-03-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by oral administration of autoantigens |
| DE4125400C2 (de) * | 1991-07-31 | 2000-08-17 | Edwin Klaus | Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen |
-
1991
- 1991-10-15 EP EP92900084A patent/EP0553291B1/en not_active Expired - Lifetime
- 1991-10-15 DE DE69133516T patent/DE69133516T2/de not_active Expired - Lifetime
- 1991-10-15 ES ES92900084T patent/ES2258261T3/es not_active Expired - Lifetime
- 1991-10-15 AT AT92900084T patent/ATE319474T1/de not_active IP Right Cessation
- 1991-10-15 KR KR1019930701083A patent/KR0140841B1/ko not_active Expired - Fee Related
- 1991-10-15 IL IL9975491A patent/IL99754A/he not_active IP Right Cessation
- 1991-10-15 HU HU9301089A patent/HUT69942A/hu unknown
- 1991-10-15 AU AU90237/91A patent/AU9023791A/en not_active Abandoned
- 1991-10-15 WO PCT/US1991/007542 patent/WO1992006708A1/en not_active Ceased
- 1991-10-15 CA CA002092905A patent/CA2092905C/en not_active Expired - Lifetime
- 1991-10-15 JP JP4500704A patent/JP2635444B2/ja not_active Expired - Lifetime
-
1993
- 1993-04-14 NO NO19931372A patent/NO314878B1/no not_active IP Right Cessation
-
1995
- 1995-06-05 US US08/463,946 patent/US6019971A/en not_active Expired - Lifetime
- 1995-09-01 AU AU30409/95A patent/AU693232B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69133516D1 (de) | 2006-05-04 |
| NO931372L (no) | 1993-05-18 |
| US6019971A (en) | 2000-02-01 |
| JP2635444B2 (ja) | 1997-07-30 |
| ATE319474T1 (de) | 2006-03-15 |
| ES2258261T3 (es) | 2006-08-16 |
| AU3040995A (en) | 1995-11-30 |
| CA2092905C (en) | 2002-01-08 |
| NO931372D0 (no) | 1993-04-14 |
| KR0140841B1 (ko) | 1998-06-01 |
| IL99754A0 (en) | 1992-08-18 |
| WO1992006708A1 (en) | 1992-04-30 |
| KR930702026A (ko) | 1993-09-08 |
| HUT69942A (en) | 1995-09-28 |
| EP0553291B1 (en) | 2006-03-08 |
| CA2092905A1 (en) | 1992-04-16 |
| JPH05508662A (ja) | 1993-12-02 |
| NO314878B1 (no) | 2003-06-10 |
| AU9023791A (en) | 1992-05-20 |
| DE69133516T2 (de) | 2006-08-10 |
| HU9301089D0 (en) | 1993-07-28 |
| EP0553291A1 (en) | 1993-08-04 |
| AU693232B2 (en) | 1998-06-25 |
| EP0553291A4 (en) | 1994-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5849298A (en) | Treatment of multiple sclerosis by oral administration of bovine myelin | |
| US6019971A (en) | Treatment of autoimmune arthritis by oral administration of collagen | |
| US5869054A (en) | Treatment of multiple sclerosis by oral administration of autoantigens | |
| EP0359783B2 (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
| US20050208061A1 (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
| AU651097B2 (en) | Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens | |
| Zhang et al. | Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. | |
| Higgins et al. | Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. | |
| JP2004026797A (ja) | ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物 | |
| AU670024B2 (en) | Methods of treating or preventing autoimmune uveoretinitis in mammals | |
| KR100263164B1 (ko) | Ii형 콜라겐의 펩티드를 유효성분으로 함유하는 콜라겐 관절염 치료제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |